Clinical Trials Browser

INDUSTRY × Fulvestrant × Thoracic × Clear all

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06257264 2026-03-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06784193 2025-10-10

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

180 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04557449 2025-10-01

CDK4i

Phase 2 Active not recruiting

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT04553133 2025-08-28

PF-07104091 as a Single Agent and in Combination Therapy

Phase 2 Active not recruiting

154 enrolled

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04606446 2025-08-13

KAT6

Phase 1 Recruiting

320 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03169738 2025-02-21

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01953926 2024-03-12

SUMMIT

Phase 2 Terminated

582 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT05905341 2023-11-08

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Phase 1 Withdrawn

BreastGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Ovarian Neoplasms

NCT04247126 2023-10-27

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Phase 1 Completed

105 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Pancreatic Neoplasms, Small Cell Lung Carcinoma

NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Phase 1 Completed

156 enrolled

BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Clinical Trials

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

CDK4i

PF-07104091 as a Single Agent and in Combination Therapy

KAT6

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

SUMMIT

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

A Study of LY3023414 in Participants With Advanced Cancer